Life Sciences Voice Top Five Newsletter

April 29, 2025

Chiesi to Acquire KalVista for $1.9 Billion, Adding Oral HAE Therapy Ekterly

April 30, 2026

Daiichi and AstraZeneca’s new drug Enhertu a possible different way to battle breast cancer

June 9, 2022

Must Read

FDA Grants Full Approval to Fabhalta for IgA Nephropathy

August 2, 2026

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

August 2, 2026

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

August 2, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Sanofi Ends Amlitelimab Development in Atopic Dermatitis After Phase 3 Program Review

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

Lilly challenges J&J in the market for psychedelic mental health by paying $2.8 billion up front for AtaiBeckley

GSK will increase its R&D efforts by investing £400 million in Britain over three years

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Top 10 Strategic Priorities for Pharmaceutical Leaders in 2026

Why Data Quality Is Becoming Pharma’s Biggest AI Challenge

The Next Wave of Innovation in Oncology

The Workforce Challenge Facing Biopharma Manufacturing

Commercial

Incyte agrees to pay $12.6M to settle kickback allegations

Editor Picks

Life Sciences Voice Top Five Newsletter

Chiesi to Acquire KalVista for $1.9 Billion, Adding Oral HAE Therapy Ekterly

Daiichi and AstraZeneca’s new drug Enhertu a possible different way to battle breast cancer

Must Read

FDA Grants Full Approval to Fabhalta for IgA Nephropathy

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

Hot Topics

About Us

Follow Us